Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma

Table 2 Demographics, clinical activity measures and IP-10 analysis of localized scleroderma (LS) patients and controls (psoriasis and healthy) participating in tissue analysis

Clinical and laboratory features of tissue analyses subjects	LS subjects	Healthy controls	Psoriasis controls
	(number = 5)	(number = 2)	(number = 2)
Demographic information	Number (%)	Number (%)	Number (%)
Female	4 (80)	1 (50)	2 (100)
Ethnicity:
Caucasian	5 (100)	1 (50)	2 (100)
African American	---	1 (50)	---
Subtype:
Linear (trunk/limb)	3 (60)	---	---
Plaque (circumscribed superficial)	2 (40)	---	---
Age	Median (IQR)	Ages in years	Ages in years
Age at onset, years	13 (6 to 16)	---	---
Age at biopsy, years	13 (10 to 16)	17, 18	34, 47
Tissue analysis	Number (%)	Number (%)	Number (%)
IP-10 staining present in cellular infiltrate	5 (100)	0 (0)	2 (100)
Degree of cellular infiltrate^a
Mild (1 to 50)	3 (60)	2 (100)	0 (0)
Moderate (51 to 150)	2 (40)	0 (0)	2 (100)
Clinical measures and plasma IP-10 of LS patients^b	Median (IQR)
PGA-A	48 (41 to 52)	---	---
mLoSSI	7 (7 to 8)	---	---
Plasma level of IP-10 (pg/ml)^c	2,814 (745 to 3,081)	---	---

^aAverage cellular infiltrate in skin: out of three high power fields: 1 to 50 = mild; 51 to 150 = moderate; >150 severe; ^bclinical and plasma measures obtained at first pediatric rheumatology visit, which was within 12 weeks of the biopsy date; ^cdetermined by Luminex assay. IP-10, interferon-gamma inducible protein-10; IQR, interquartile range; mLoSSI, modified Localized Scleroderma Skin Score; PGA-A, physicians global assessment of activity.

ISSN: 1478-6362